NCT04947995 (MONITOR- GAC) is a clinical trial of ctDNA multi-omics test in Gastric Cancer, sponsored by GeneCast Biotechnology Co., Ltd..

Who is sponsoring NCT04947995?

NCT04947995 is sponsored by GeneCast Biotechnology Co., Ltd..

What drugs are being tested in NCT04947995?

Interventions in NCT04947995: ctDNA multi-omics test.

What condition does NCT04947995 study?

NCT04947995 studies Gastric Cancer.

Is NCT04947995 still recruiting?

NCT04947995 is currently status unknown. Last updated 1 July 2021.

Last reviewed 2021-07-01 · How we verify

NCT04947995: MONITOR- GAC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multi-Omics Noninvasive Inspection of TumOr Risk for Gastric Cancer

Status unknown Last updated 1 July 2021

What this trial tests

trial testing ctDNA multi-omics test in Gastric Cancer in 450 participants. Status unknown.

Timeline

15 June 2021

Primary endpoint
15 June 2023

15 June 2023

Quick facts

Lead sponsor	GeneCast Biotechnology Co., Ltd.
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	450
Start date	15 June 2021
Primary completion	15 June 2023
Estimated completion	15 June 2023
Sites	1 location across China

Drugs / interventions tested

ctDNA multi-omics test

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

GeneCast Biotechnology Co., Ltd.

Who can join

Adults 40 to 88, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, case-control study intended to develop and validate a blood-based multi-omics assay and computational model for early detection of gastric cancer. Approximately 450 subjects who receive esophageogastroscopy (EGD) will be enrolled and assigned to three arms including gastric cancer, precancerous lesion, and healthy control based on the diagnosis of EGD and histological results. Cell free DNA will be extracted from peripheral blood of all participants and assayed by next-generation sequencing for biomarkers including somatic mutation, methylation, and chromosome instability signals. In the first stage a multi-omics models will be developed for classification between malignancy group and control groups, and between precancerous group and healthy control. Sensitivity and specificity of the model will be evaluated in an independent validation group in the second stage.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Novel biomarkers for early detection of gastric cancer.
Matsuoka T, Yashiro M. · · 2023 · cited 60× · PMID 37213407 · DOI 10.3748/wjg.v29.i17.2515
Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy.
Wang X, Wang L, Lin H, Zhu Y, et al · · 2024 · cited 54× · PMID 38333685 · DOI 10.3389/fonc.2024.1303335
The Role of ctDNA in Gastric Cancer.
Mencel J, Slater S, Cartwright E, Starling N. · · 2022 · cited 26× · PMID 36291888 · DOI 10.3390/cancers14205105
Clinical applications and perspectives of circulating tumor DNA in gastric cancer.
Li JH, Zhang DY, Zhu JM, Dong L. · · 2024 · cited 14× · PMID 38184573 · DOI 10.1186/s12935-024-03209-4
Translational Bioinformatics Applied to the Study of Complex Diseases.
Casotti MC, Meira DD, Alves LNR, Bessa BGO, et al · · 2023 · cited 12× · PMID 36833346 · DOI 10.3390/genes14020419
DNA methylation biomarkers for early detection of gastric and colorectal cancers.
Gao X, Liu H, Yu J, Nie Y. · · 2024 · cited 5× · PMID 38318978 · DOI 10.20892/j.issn.2095-3941.2023.0443

Verify or expand the search:

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Other GeneCast Biotechnology Co., Ltd. trials

Trials by the same sponsor.

NCT05668910 — Gastric Cancer Early Detection by Multi-dimensional Analysis of cfDNA · unknown
NCT04923802 — Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION) · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04947995 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GeneCast Biotechnology Co., Ltd.
Last refreshed: 1 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04947995.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing